Inhaled Salmeterol/Fluticasone Propionate Combination
- 1 November 2000
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 60 (5) , 1207-1233
- https://doi.org/10.2165/00003495-200060050-00012
Abstract
The long-acting β2-agonist salmeterol and the corticosteroid fluticasone propionate are available as a combination inhalation device for the treatmentKeywords
This publication has 33 references indexed in Scilit:
- Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 μ g twice daily and budesonide 800 μ g twice daily in the treatment of adults and adolescents with asthmaRespiratory Medicine, 2000
- The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthmaAnnals of Allergy, Asthma & Immunology, 1999
- Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthmaAnnals of Allergy, Asthma & Immunology, 1999
- Ligand-independent Activation of the Glucocorticoid Receptor by β2-Adrenergic Receptor Agonists in Primary Human Lung Fibroblasts and Vascular Smooth Muscle CellsJournal of Biological Chemistry, 1999
- The complementary role of glucocorticosteroids and long‐acting β‐adrenergic agonistsAllergy, 1998
- SalmeterolDrugs, 1997
- Salmeterol: A study by Prescription Event Monitoring in a UK cohort of 15,407 patientsJournal of Clinical Epidemiology, 1996
- Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroidThe Lancet, 1994
- Inhaled Fluticasone PropionateDrugs, 1994
- Salmeterol XinafoateDrugs, 1991